Bénédicte Lallemand

This inventor holds 5 USPTO granted patents. Top assignees: Ucb Pharma, S.a., Ucb S.a., Uob Pharma, S.a.. Active years: 2005-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bénédicte Lallemand. Retrieved from https://idiyas.com/inventor/bénédicte-lallemand

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 5

% Patents Active = 40.0

Average Co-Inventor Count = 5.5

ph-index = 4

Forward Citations = 29(Granted Patents)

Location History:

Waimes, BE (2005 - 2011)
Namur, BE (2013)

Company Filing History:

Years Active: 2005-2013

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8492416 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2013-07-23),

2. 8034958 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2011-10-11),

3. 7692028 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2010-04-06),

4. 7358276 - 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2008-04-15),

5. 6911461 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2005-06-28),

Title: The Innovator Bénédicte Lallemand: Advancements in Neurological Treatments

Introduction: Bénédicte Lallemand, an accomplished inventor based in Waimes, Belgium, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of five patents, his work focuses on innovative solutions for treating neurological disorders.

Latest Patents: Bénédicte's latest patents revolve around 2-oxo-1-pyrrolidine derivatives. These compounds, defined by specific substituents in the patent specifications, showcase strong potential for use as pharmaceuticals. Notably, these derivatives are particularly effective in treating neurological disorders such as epilepsy, marking a significant advancement in therapeutic options.

Career Highlights: His career has been closely associated with leading companies in the pharmaceutical industry, including UCB S.A. and UCB Pharma S.A. Here, Bénédicte has honed his skills and contributed his expertise towards groundbreaking inventions in drug development.

Collaborations: Throughout his career, Bénédicte has collaborated with notable colleagues such as Benoît Kenda and Patrick Pasau. These professional relationships have enriched his innovative efforts and have driven the success of many projects he has been a part of.

Conclusion: Bénédicte Lallemand's contributions to the pharmaceutical industry, specifically through the development of 2-oxo-1-pyrrolidine derivatives, reflect his dedication to improving treatment options for neurological disorders. His innovative approach and commitment to research continue to inspire advancements within the field.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]